Vical Inc. (NASDAQ:VICL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $3.50 price objective on the stock. Zacks Investment Research’s target price indicates a potential upside of 9.72% from the company’s previous close.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Separately, HC Wainwright reiterated a “buy” rating on shares of Vical in a research report on Tuesday, July 19th.
Shares of Vical (NASDAQ:VICL) opened at 3.19 on Wednesday. Vical has a 1-year low of $2.80 and a 1-year high of $5.40. The firm’s market capitalization is $29.37 million. The company’s 50-day moving average is $3.93 and its 200 day moving average is $4.07.
Vical (NASDAQ:VICL) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.14. Vical had a negative net margin of 30.81% and a negative return on equity of 14.18%. The company earned $4.10 million during the quarter, compared to analysts’ expectations of $4.50 million. On average, analysts expect that Vical will post ($0.86) EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. BlackRock Fund Advisors boosted its stake in shares of Vical by 32.5% in the second quarter. BlackRock Fund Advisors now owns 23,459 shares of the company’s stock worth $106,000 after buying an additional 5,750 shares during the period. Eagle Global Advisors LLC bought a new stake in Vical during the second quarter valued at $178,000. ClariVest Asset Management LLC bought a new stake in Vical during the second quarter valued at $208,000. Finally, Renaissance Technologies LLC boosted its stake in Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the company’s stock valued at $811,000 after buying an additional 476,499 shares during the last quarter. Institutional investors and hedge funds own 31.48% of the company’s stock.
Vical Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.